CareDx Inc (CDNA)
21.94
-1.55 (-6.60%)
USD |
NASDAQ |
Jun 28, 16:00
21.94
0.00 (0.00%)
After-Hours: 17:57
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.168B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -74.67% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.749 |
| Price to Book Value | 2.552 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 87.64% |
News
Headline
Wire
Time (ET)
Globe Newswire
06/28 12:00
PR Newswire
06/28 05:45
PR Newswire
06/27 22:23
PR Newswire
06/27 16:30
PR Newswire
06/27 11:00
Globe Newswire
06/27 10:24
PR Newswire
06/27 09:03
Globe Newswire
06/25 16:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 07/29/2022* | -- | Results | Q2 2022 | -- | -0.11 | -- | |
| 07/29/2022* | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/05/2022 | -- | Results | Q1 2022 | -0.13 | -0.03 | -387.4% | |
| 05/05/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/24/2022 | -- | Results | Q4 2021 | -0.03 | 0.03 | -192.3% | |
| 02/24/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 10/28/2021 | -- | Results | Q3 2021 | 0.07 | 0.02 | 250.0% | |
| 10/28/2021 | 16:30 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a leading provider of genomics-based information for transplant patients. Its primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia and Stockholm, Sweden. |
| URL | https://www.caredx.com |
| Investor Relations URL | https://investors.caredxinc.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Jul. 29, 2022 (est.) |
| Last Earnings Release | May. 05, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of June 27, 2022.
Fundamentals
| Revenue (TTM) | 308.41M |
| Total Expenses (TTM) | 356.33M |
| Net Income (TTM) | -49.62M |
| Total Assets (Quarterly) | 546.71M |
| Total Liabilities (Quarterly) | 89.17M |
| Shareholders Equity (Quarterly) | 457.54M |
| Cash from Operations (TTM) | -7.132M |
| Cash from Investing (TTM) | -127.40M |
| Cash from Financing (TTM) | -2.721M |
Ratings
Profile
Edit
| CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a leading provider of genomics-based information for transplant patients. Its primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia and Stockholm, Sweden. |
| URL | https://www.caredx.com |
| Investor Relations URL | https://investors.caredxinc.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Jul. 29, 2022 (est.) |
| Last Earnings Release | May. 05, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CDNA Tweets |